Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179)
:2179
Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$5.00
▲(19.62% Upside)
Action:UpgradedDate:01/29/26
The score is primarily weighed down by weak financial performance (declining revenue, persistent losses, and negative operating/free cash flow) and balance sheet leverage risk. Technical signals are neutral-to-mixed, providing limited support, while valuation is constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Innovative Product Pipeline
The focus on innovative vaccine development positions Recbio to capitalize on growing global demand for effective disease prevention solutions.
Negative Factors
Declining Revenue
Decreasing revenue reflects challenges in market penetration or product adoption, potentially impacting long-term financial stability and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Pipeline
The focus on innovative vaccine development positions Recbio to capitalize on growing global demand for effective disease prevention solutions.
Read all positive factors
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.96B
Dividend YieldN/A
Average Volume (3M)18.23K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue GrowthN/A
EPS Growth-18.99%
CountryHK
Employees531
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding316,138,700
10 Day Avg. Volume1,300
30 Day Avg. Volume18,233
Financial Highlights & Ratios
PEG Ratio3.04
Price to Book (P/B)8.14
Price to Sales (P/S)159.51
P/FCF Ratio-6.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and ...
How the Company Makes Money
Jiangsu Recbio Technology Co., Ltd. generates revenue through several key streams, primarily from the sale of vaccines and related biopharmaceutical products. The company engages in research and development (R&D) of vaccines, which, once commercia...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.11M | 27.00M | 30.38M | 5.33M | 6.20M | 1.46M |
| Gross Profit | 26.20M | 15.95M | 22.34M | 5.33M | 6.20M | 1.46M |
| EBITDA | -577.66M | -523.97M | -569.87M | -847.67M | -590.00M | -134.91M |
| Net Income | -653.91M | -562.39M | -571.96M | -719.20M | -657.56M | -179.40M |
Balance Sheet | ||||||
| Total Assets | 1.54B | 1.94B | 2.19B | 2.31B | 1.92B | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 104.20M | 448.31M | 837.76M | 1.33B | 1.18B | 681.71M |
| Total Debt | 839.95M | 889.10M | 650.79M | 282.63M | 76.72M | 26.13M |
| Total Liabilities | 1.37B | 1.41B | 1.12B | 656.53M | 245.92M | 2.06B |
| Stockholders Equity | 177.63M | 529.32M | 1.07B | 1.66B | 1.67B | -1.01B |
Cash Flow | ||||||
| Free Cash Flow | -278.63M | -636.66M | -862.18M | -888.04M | -710.79M | -241.07M |
| Operating Cash Flow | -184.88M | -464.82M | -638.07M | -579.54M | -472.92M | -70.34M |
| Investing Cash Flow | -214.61M | -279.04M | 9.42M | -378.43M | 68.70M | -258.59M |
| Financing Cash Flow | 0.00 | 218.06M | 275.27M | 839.44M | 1.23B | 680.38M |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Negative
4.18
Price Trends
4.62
Negative
4.99
Negative
6.32
Negative
Market Momentum
-0.12
Positive
39.02
Neutral
45.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 4.18 is below the 20-day moving average (MA) of 4.29, below the 50-day MA of 4.62, and below the 200-day MA of 6.32, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 39.02 is Neutral, neither overbought nor oversold. The STOCH value of 45.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$1.96B | -3.21 | -184.99% | ― | ― | -18.99% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.90
-41.43%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.41
214.47%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2616
CStone Pharmaceuticals
9.35
7.15
325.00%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.59
50.43%
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Recbio’s Shingles Vaccine NDA Accepted by China Regulator
Dec 29, 2025
Jiangsu Recbio announced that China’s Center for Drug Evaluation has officially accepted the new drug application for its novel adjuvanted recombinant shingles vaccine REC610, which uses the company’s proprietary BFA01 adjuvant to boos...
Jiangsu Recbio Reshapes Board Leadership, Appoints Xu Haoyu as New Chairman
Dec 23, 2025
Jiangsu Recbio Technology has announced a leadership reshuffle, with founder-executive Dr. Liu Yong stepping down as chairman of the board and head of the nomination committee to focus on other commitments while remaining as an executive director ...
Jiangsu Recbio Sets Out Board Line-up and Committee Roles
Dec 23, 2025
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, led by chairman and non-executive director Xu Haoyu, and including a mix of executive, non-executive and independent non-executive directors such ...
Jiangsu Recbio Shareholders Approve Governance Overhaul and Board Changes
Dec 19, 2025
Jiangsu Recbio Technology Co., Ltd. announced that shareholders at its 19 December 2025 extraordinary general meeting approved a series of corporate governance changes, including the abolishment of its Supervisory Board and related amendments to i...
Jiangsu Recbio Sets Out Board and Committee Structure
Dec 19, 2025
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive directors, with Dr. Liu Yong serving as chairman. The company has also detailed ...
Jiangsu Recbio Technology Completes Issuance of Domestic Shares, Reshaping Shareholding Structure
Dec 17, 2025
Jiangsu Recbio Technology Co., Ltd. announced the completion of the issuance of 143,112,702 fully paid Domestic Shares, increasing its total issued shares to 626,075,702. This issuance significantly altered its shareholding structure, granting Yan...
Jiangsu Recbio Technology Announces Key Governance Changes
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has announced an extraordinary general meeting scheduled for December 19, 2025, to discuss significant corporate governance changes, including the abolishment of the Supervisory Board and amendments to the Artic...
Jiangsu Recbio Announces Board Composition and Roles
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides insights into the company’s governance structure, which is crucial f...
Jiangsu Recbio Strengthens Governance with New Nomination Committee
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure by regulating the appointment of directors and senior management. This move aims to rationalize the board’s composition and improv...
Jiangsu Recbio Enhances Governance with New Committee
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration plans for directors and senior management. This move aims to create ...
Jiangsu Recbio Technology Strengthens Governance with New Audit Committee
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has established an audit committee as part of its board to enhance decision-making, improve internal controls, and ensure effective supervision and management. The committee, composed mainly of independent non-e...
Jiangsu Recbio Announces Leadership Changes and New Appointments
Dec 1, 2025
Jiangsu Recbio Technology Co., Ltd. has announced significant changes in its leadership structure, including the resignation of three directors and the appointment of new directors. The company is actively seeking to maintain gender diversity on i...
Jiangsu Recbio Completes Capital Alteration and Updates Business License
Nov 25, 2025
Jiangsu Recbio Technology Co., Ltd. has completed the industrial and commercial registration for its registered capital alteration, following the issuance of domestic shares to target subscribers. The company’s registered capital has increas...
Jiangsu Recbio Expands Drug Production License for Shingles Vaccine
Nov 14, 2025
Jiangsu Recbio Technology Co., Ltd. has received approval to expand its Drug Production License to include the recombinant shingles vaccine and its adjuvant components. This expansion enhances the company’s RD and production capabilities, al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.